Ampersand Capital Partners Invests in iuvo BioScience
September 28, 2022
Ampersand Capital Partners has agreed to acquire a stake in iuvo BioScience, a Rochester-based specialty CRO that provides laboratory, preclinical, clinical development, and scientific consulting services. The investment will fund expansion of iuvo's integrated service portfolio and laboratory capacity and support an active inorganic (add-on) growth strategy; founders Ben Burton and Mary Richardson will remain in leadership roles and as shareholders.
- Buyers
- Ampersand Capital Partners
- Targets
- iuvo BioScience
- Industry
- Healthcare Services
- Location
- New York, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Canyon Labs Acquires iuvo BioScience's Lab Services and Scientific Consulting Divisions
January 7, 2025
Healthcare Services
Canyon Labs has acquired the laboratory services and scientific consulting businesses of iuvo BioScience, integrating the lab and consulting personnel into Canyon Labs' operations while iuvo retains its ophthalmic clinical research team. The deal expands Canyon Labs' testing and consulting capabilities (adding a Rochester, NY site) and allows iuvo to sharpen its focus on ophthalmic clinical trial services.
-
Ampersand Capital Partners Makes Growth Investment in VIVEbiotech
December 4, 2024
Biotechnology
Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.
-
Ampersand Capital Partners Acquires Biologos LLC
March 19, 2024
Biotechnology
Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.
-
iuvo BioScience Acquires Promedica International
January 18, 2024
Healthcare Services
iuvo BioScience, a Rochester-based specialty preclinical and clinical services provider backed by Ampersand Capital Partners, has acquired Promedica International, an ophthalmology-focused clinical CRO headquartered in Costa Mesa, California. The deal combines iuvo's laboratory and consulting capabilities with Promedica's ophthalmic clinical trial expertise to create an integrated end-to-end ophthalmology clinical research offering.
-
Ampersand Capital Partners Invests in AnaBios Corporation
June 7, 2022
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.
-
Ampersand Capital Partners Invests in BioEcho Life Sciences
March 1, 2022
Biotechnology
Ampersand Capital Partners made a minority growth equity investment in Cologne-based BioEcho Life Sciences to support the company's global expansion, new product launches, and expansion of its direct salesforce. As part of the transaction Ampersand appointed Frank Witney and Arya Mehrabanzad to BioEcho's board; financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.